BOOG Study Center
S.C. Linn, H.M. Oosterkamp en M. Kok
Dr. E. van Leeuwen-Stok, BOOG Study Center
Rosie Voorthuis
Phone 020 – 512 7951
E-mail r.voorthuis@nki.nl
tripleB@nki.nl
Contact gegevens centraal datamanagement TRIPLE-B:
b.dufourny@nki.nl tel 020 512 9046
Randomization:
NKI Data Center, Trial Office Phone +31 20 512 2668
Fax +31 20 512 2679 E-mail trial@nki.nl
Central contact NKI Data Center:
I. Mandjes Phone +31 20 512 2880 E-mail i.mandjes@nki.nl
NKI Data Center:
Karin Kaptijn
Phone +31 20 512 2655
E-mail k.kaptijn@nki.nl
IKNL / centrum zelf
Roche grant
Immunohubs (aangestelde centra voor extra bloedbuizen en biopten)(status 26nov2018): NKI-AvL
tripleB@nki.nl
Primary:
Secondary:
* BRCA-like status determined by array comparative genomic hybridization (aCGH), multiplex ligase-dependent probe amplification (MLPA), or next generation sequencing (NGS); BRCA-like test positive when the genomic profile resembles that of BRCA-mutated breast cancers (BRCA-like genomic profile, derived from BRCA1 or BRCA2 mutation), or when the tumor is BRCA1-mutated, BRCA2-mutated, the patient is a BRCA1 and/or BRCA2 germline mutation carrier, or has a BRCA1 promoter hypermethylation.
Primary endpoint:
Primary Outcome Measure (2×2 factorial design):
Secondary Outcome Measures: